MicroVision (MVIS) CEO acquires 187,900 new shares from company

Rhea-AI Filing Summary

MicroVision, Inc. CEO Glen W. DeVos reported an acquisition of company stock. On March 15, 2026, he acquired 187,900 shares of MicroVision common stock directly from the company at $0.5322 per share under a Subscription Agreement, matching the March 13, 2026 closing price.

Following this transaction, DeVos directly holds 187,900 shares. A footnote states the purchase is intended to be an exempt transaction pursuant to Rule 16b-3.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DeVos Glen W.

(Last) (First) (Middle)

18390 NE 68TH STREET

(Street)

REDMOND WA 98052

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MICROVISION, INC. [ MVIS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO

3. Date of Earliest Transaction (Month/Day/Year)
03/15/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(1)	03/15/2026		A(2)		187,900	A	$0.5322	187,900	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Pursuant to a Subscription Agreement executed on March 15, 2026 between MicroVision, Inc. ("MicroVision") and the reporting person, the reporting person acquired 187,900 shares of MicroVision's common stock directly from MicroVision at a purchase price of $0.5322 per share, the closing price of MicroVision's common stock on March 13, 2026.

2. The purchase is intended to be an exempt transaction pursuant to Rule 16b-3.

	/s/ Drew G. Markham, attorney-in-fact for Glen DeVos	03/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did MicroVision (MVIS) report for its CEO?

MicroVision reported that CEO Glen W. DeVos acquired 187,900 shares of its common stock. The shares were obtained directly from MicroVision under a Subscription Agreement executed on March 15, 2026, and are reflected as a direct ownership position in the filing.

How many MicroVision (MVIS) shares did the CEO acquire and at what price?

Glen W. DeVos acquired 187,900 shares of MicroVision common stock at $0.5322 per share. A footnote explains this price equals the closing price of MicroVision’s common stock on March 13, 2026, and was used for the Subscription Agreement purchase.

Did the MicroVision (MVIS) CEO buy shares on the open market?

No, the CEO did not buy shares on the open market. A footnote states he acquired 187,900 shares directly from MicroVision pursuant to a Subscription Agreement, at $0.5322 per share, rather than through public market purchases.

What is Glen W. DeVos’s MicroVision (MVIS) shareholding after this transaction?

After the reported transaction, Glen W. DeVos directly holds 187,900 shares of MicroVision common stock. The Form 4 lists this figure as the total shares beneficially owned following the acquisition on March 15, 2026, under the non-derivative holdings section.

How is Rule 16b-3 referenced in the MicroVision (MVIS) CEO’s share acquisition?

A footnote states the CEO’s purchase is intended to be an exempt transaction pursuant to Rule 16b-3. This note applies to the 187,900-share acquisition under the Subscription Agreement described in the Form 4, highlighting the intended regulatory treatment.